Methods
Nextstellis®: A new drug update
A new combined oral contraceptive was approved by the FDA (Nextstellis®) in April 2021.1 Nextstellis contains estetrol, an estrogen that can be manufactured from plants and that was originally…
Levonorgestrel Intrauterine Device for Emergency Contraception
A new research study evaluates levonorgestrel IUD for emergency contraception
Outreach Initiative to Expand Access to Depot Medroxyprogesterone Acetate (DMPA)
New training program by Birth Control Pharmacist and Provide includes pharmacy best practices to combat stigma and communication guides and online resources to help connect patients with local resources.
Meet Phexxi – A New Non-Hormonal Contraceptive Gel
About the Product Lactic acid, citric acid, and potassium bitartrate (Phexxi, Evofem Biosciences) is a prescription combination, non-hormonal contraceptive gel approved by the FDA in May 2020. The vaginal gel…
Clinical Considerations for Contraception During COVID: Extended Duration of IUDs and Implants
During the COVID-19 pandemic and beyond, patients may desire a contactless method of contraception. The subcutaneous (SQ) formulation of depot medroxyprogesterone acetate (DMPA), Depo-SubQ Provera, is an important option to offer patients. This may be of particular interest among patients who currently come in to the pharmacy or go to a clinic for their intramuscular (IM) injection.
Clinical Considerations for Contraception During COVID: Patient Self-Administration
During the COVID-19 pandemic and beyond, patients may desire a contactless method of contraception. The subcutaneous (SQ) formulation of depot medroxyprogesterone acetate (DMPA), Depo-SubQ Provera, is an important option to offer patients. This may be of particular interest among patients who currently come in to the pharmacy or go to a clinic for their intramuscular (IM) injection.